<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">PEN</journal-id>
<journal-id journal-id-type="hwp">sppen</journal-id>
<journal-id journal-id-type="nlm-ta">JPEN J Parenter Enteral Nutr</journal-id>
<journal-title>Journal of Parenteral and Enteral Nutrition</journal-title>
<issn pub-type="ppub">0148-6071</issn>
<issn pub-type="epub">1941-2444</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0148607111413770</article-id>
<article-id pub-id-type="publisher-id">10.1177_0148607111413770</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Communications</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Gastrointestinal Hormone Concentrations Associated With Gastric Feeding in Critically Ill Patients</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Crona</surname><given-names>Daniel</given-names></name>
<degrees>PharmD</degrees>
<xref ref-type="aff" rid="aff1-0148607111413770">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>MacLaren</surname><given-names>Robert</given-names></name>
<degrees>PharmD, FCCM, FCCP</degrees>
<xref ref-type="aff" rid="aff2-0148607111413770">2</xref>
</contrib>
</contrib-group>
<aff id="aff1-0148607111413770"><label>1</label>University of North Carolina Eshelman School of Pharmacy, Chapel Hill, North Carolina</aff>
<aff id="aff2-0148607111413770"><label>2</label>University of Colorado School of Pharmacy, Aurora, Colorado</aff>
<author-notes><corresp id="corresp1-0148607111413770">Robert MacLaren, PharmD, University of Colorado School of Pharmacy, AO1, C238-L15, 12631 East 17th Ave, Aurora, CO 80045; e-mail: <email>rob.maclaren@ucdenver.edu</email>.</corresp></author-notes>
<pub-date pub-type="epub-ppub">
<month>3</month>
<year>2012</year>
</pub-date>
<volume>36</volume>
<issue>2</issue>
<fpage>189</fpage>
<lpage>196</lpage>
<history>
<date date-type="received">
<day>1</day>
<month>1</month>
<year>2010</year>
</date>
<date date-type="accepted">
<day>18</day>
<month>1</month>
<year>2011</year>
</date>
</history>
<permissions>
<copyright-statement>© 2012 The American Society for Parenteral and Enteral Nutrition</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">The American Society for Parenteral and Enteral Nutrition</copyright-holder>
</permissions>
<abstract>
<p><italic>Background</italic>: Altered concentrations of ghrelin, motilin, and cholecystokinin (CCK) may contribute to gastric hypomotility. The aims of this study were to evaluate the concentrations of these hormones in patients tolerant and intolerant to gastric nutrition, assess the influence of prokinetic therapy on these hormone concentrations, determine the associations between these mediators and gastric emptying, and evaluate whether inflammation influences their concentrations. <italic>Methods</italic>: Post hoc analyses of 2 prospective studies that enrolled 20 critically ill patients with an aspirated gastric residual (GR) &gt;150 mL while receiving gastric enteral nutrition (intolerant group) and 10 critically ill patients with minimal GR (tolerant group). Patients with intolerance were also assessed 1 day after prokinetic therapy. Fasting serum concentrations of total ghrelin, acyl ghrelin (active), des-acyl ghrelin (inactive), motilin, CCK, and tumor necrosis factor (TNF)−α were determined. Gastric emptying was assessed concurrently using the acetaminophen absorption method. <italic>Results</italic>: Compared to the tolerant group, the intolerant group had higher total ghrelin (1324.8 ± 1204.6 vs 285.1 ± 132.5 pg/mL; <italic>P</italic> &lt; .001), lower acyl ghrelin (70.5 ± 65.4 vs 208.5 ± 186.9 pg/mL; <italic>P</italic> &lt; .05), and lower acyl ghrelin to des-acyl ghrelin ratio (1.11 ± 1.35 vs 3.47 ± 3.21 pg/mL; <italic>P</italic> &lt; .05). Concentrations of other hormones and TNF-α were similar. Despite accelerated gastric emptying after prokinetic therapy, concentrations of all hormones and TNF-α were similar to baseline values. Hormone concentrations were not associated with gastric emptying or TNF-α. <italic>Conclusion</italic>: Patients intolerant to gastric nutrition generate less acyl ghrelin, which may contribute to gastric hypomotility. Intolerance is not associated with altered concentrations of other hormones. Hormone concentrations are not influenced by prokinetic therapy.</p>
</abstract>
<kwd-group>
<kwd>ghrelin</kwd>
<kwd>motilin</kwd>
<kwd>cholecystokinin</kwd>
<kwd>enteral nutrition</kwd>
<kwd>metoclopramide</kwd>
<kwd>erythromycin</kwd>
<kwd>intensive care</kwd>
<kwd>critical care</kwd>
<kwd>feeding intolerance</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0148607111413770">
<title>Clinical Relevancy Statement</title>
<p>This post hoc analysis is clinically relevant because it explores pathophysiologic mechanisms of gastrointestinal dysfunction associated with critical illness and, if validated, may promote the development of possible therapeutic options that are specifically directed at an etiology.</p>
</sec>
<sec id="section2-0148607111413770" sec-type="intro">
<title>Introduction</title>
<p>Many practice guidelines recommend starting enteral nutrition (EN) within 24 hours of intensive care unit (ICU) admission<sup><xref ref-type="bibr" rid="bibr1-0148607111413770">1</xref>-<xref ref-type="bibr" rid="bibr4-0148607111413770">4</xref></sup> because the early provision of EN is associated with reduced rates of infection and mortality, shortened stay in the ICU, and lower ICU costs.<sup><xref ref-type="bibr" rid="bibr5-0148607111413770">5</xref>-<xref ref-type="bibr" rid="bibr8-0148607111413770">8</xref></sup> Gastric motility dysfunction occurs frequently in critically ill patients and limits the administration of EN.<sup><xref ref-type="bibr" rid="bibr9-0148607111413770">9</xref>-<xref ref-type="bibr" rid="bibr15-0148607111413770">15</xref></sup> A common manifestation of motility dysfunction is the development of high volumes of aspirated gastric residuals.<sup><xref ref-type="bibr" rid="bibr9-0148607111413770">9</xref>-<xref ref-type="bibr" rid="bibr26-0148607111413770">26</xref></sup> Patients with gastric motility dysfunction are at increased risk of aspiration and have lengthened ICU stays and higher mortality rates.<sup><xref ref-type="bibr" rid="bibr26-0148607111413770">26</xref>-<xref ref-type="bibr" rid="bibr32-0148607111413770">32</xref></sup></p>
<p>The etiologies of gastrointestinal emptying abnormalities in ICU patients are multifactorial. A common pathophysiologic link is the impaired activity of phase III contractions of the migrating motor complex (MMC) of the gastric antrum and the subsequent generation of dyskinetic contractions through the small bowel.<sup><xref ref-type="bibr" rid="bibr9-0148607111413770">9</xref>-<xref ref-type="bibr" rid="bibr11-0148607111413770">11</xref></sup> Neuroendocrine abnormalities may contribute to these pathologic processes. Serum concentrations of cholecystokinin (CCK) and peptide YY (PYY), 2 hormones that inhibit gastrointestinal motility, are elevated in critical illness.<sup><xref ref-type="bibr" rid="bibr33-0148607111413770">33</xref>-<xref ref-type="bibr" rid="bibr36-0148607111413770">36</xref></sup> The expression of CCK is particularly heightened when EN intolerance is present. Ghrelin and motilin stimulate gastric emptying by inducing the MMC.<sup><xref ref-type="bibr" rid="bibr37-0148607111413770">37</xref>,<xref ref-type="bibr" rid="bibr38-0148607111413770">38</xref></sup> Ghrelin is primarily secreted from gastric epithelial cells but requires posttranslational acylation for activity.<sup><xref ref-type="bibr" rid="bibr38-0148607111413770">38</xref>-<xref ref-type="bibr" rid="bibr42-0148607111413770">42</xref></sup> In contrast, motilin is secreted as an active moiety by endocrine cells located in the duodeno-jejunal mucosa.<sup><xref ref-type="bibr" rid="bibr38-0148607111413770">38</xref></sup> Although inflammation suppresses centrally mediated gastric motility, both ghrelin and motilin possess anti-inflammatory activity.<sup><xref ref-type="bibr" rid="bibr39-0148607111413770">39</xref>-<xref ref-type="bibr" rid="bibr42-0148607111413770">42</xref></sup> Inflammatory states are associated with elevated ghrelin concentrations.<sup><xref ref-type="bibr" rid="bibr38-0148607111413770">38</xref>-<xref ref-type="bibr" rid="bibr45-0148607111413770">45</xref></sup> The primary purpose of this study was to comparatively evaluate the expression of CCK, ghrelin, and motilin in patients tolerant and intolerant to gastric EN. Secondary objectives assessed the influence of prokinetic agents on the hormone concentrations, the associations between these mediators and gastric emptying, and whether their expression is influenced by inflammation. This post hoc analysis is clinically relevant because it explores pathophysiologic mechanisms of gastrointestinal dysfunction associated with critical illness and, if validated, may promote the development of possible therapeutic options that are specifically directed at an etiology.</p>
</sec>
<sec id="section3-0148607111413770" sec-type="materials|methods">
<title>Methods and Materials</title>
<sec id="section4-0148607111413770">
<title>Patients</title>
<p>This study was a post hoc analysis of data generated from 2 previously published trials.<sup><xref ref-type="bibr" rid="bibr46-0148607111413770">46</xref>,<xref ref-type="bibr" rid="bibr47-0148607111413770">47</xref></sup> The first study comparatively assessed erythromycin and metoclopramide for facilitating gastric emptying in critically ill patients with intolerance to gastric EN.<sup><xref ref-type="bibr" rid="bibr46-0148607111413770">46</xref></sup> The second study compared gastric emptying function in the cohort of critically ill patients with intolerance to a group of critically ill patients tolerating gastric EN.<sup><xref ref-type="bibr" rid="bibr47-0148607111413770">47</xref></sup> All protocols were reviewed and approved by the Institutional Review Board of the University of Colorado Health Sciences Center. Patients were enrolled from 1 of 3 ICUs (a 16-bed medical ICU, a 16-bed surgical ICU, or an 8-bed neurosurgical ICU). Written informed consent and Health Insurance Portability and Accountability authorization were obtained from each patient or next of kin.</p>
<p>The inclusion and exclusion criteria are extensively described in previous publications.<sup><xref ref-type="bibr" rid="bibr46-0148607111413770">46</xref>,<xref ref-type="bibr" rid="bibr47-0148607111413770">47</xref></sup> Briefly, critically ill, mechanically ventilated patients between the ages of 18 and 85 years were eligible for enrollment in the original studies if they were receiving continuous nasogastric or orogastric administration of EN. Intolerance was defined as a single aspirated gastric residual volume &gt;150 mL, unless the aspirate was measured within 4 hours of enteral administration of contrast media, sterile water, or medications. Tolerance was defined as the administration of at least 75% of the patient’s daily energy requirements and cumulative residual volumes ≤120 mL in the 24-hour period before enrollment and each individual measurement ≤30 mL. An institution-specific protocol guided EN administration. Exclusion criteria included the administration of prokinetic agents within 24 hours of enrollment, hemodynamic instability, malabsorptive gastrointestinal disorders, abnormal liver function, active renal replacement therapy, pregnancy, and morbid obesity.</p>
</sec>
<sec id="section5-0148607111413770">
<title>Study Design</title>
<p>The study protocols have been previously described in detail.<sup><xref ref-type="bibr" rid="bibr46-0148607111413770">46</xref>,<xref ref-type="bibr" rid="bibr47-0148607111413770">47</xref></sup> Briefly, the acetaminophen absorption method was used to evaluate gastric emptying. Within 6 hours of study enrollment, all patients received 975 mg of enteral acetaminophen as 30 mL of undiluted syrup (32.5 mg/mL) followed by sterile water flushes of 20 mL through the feeding tube. The stomach was emptied prior to the administration of acetaminophen, and EN was discontinued when blood samples were collected. Ten venous blood samples of 3 mL were serially collected over 6 hours from an indwelling catheter by a study investigator. The study ceased at this point for patients tolerant to gastric EN. Patients intolerant to EN were randomized to receive 4 doses of erythromycin 250 mg infused over 30 minutes or metoclopramide 10 mg administered by intravenous bolus, each administered every 6 hours. Thirty minutes after the fourth dose, the acetaminophen absorption assessment was repeated. All blood samples were collected in test tubes without heparin and transported on ice. Plasma was separated from the remaining cellular material by centrifugation at 3000 rpm for 15 minutes. Plasma samples were placed in labeled polyethylene vials, frozen at −80°C, and stored until assayed.</p>
</sec>
<sec id="section6-0148607111413770">
<title>Analytical Analyses</title>
<p>Acetaminophen concentrations were determined at each time point in duplicate by a fluorescence polarization assay (TDxFLx; Abbott Diagnostics, Chicago, IL) and the mean concentration at each time point was used for pharmacokinetic analysis. Noncompartmental analysis of acetaminophen concentrations with WinNonlin version 5.0.1 (Pharsight Corporation, Mountain View, CA) was used to determine the area under the concentration-time curve for 60 minutes (AUC<sub>60</sub>), concentration at 60 minutes (C<sub>60</sub>), peak concentration (C<sub>max</sub>), and time to peak concentration (t<sub>max</sub>). During the determination of acetaminophen concentrations, plasma samples were treated with the irreversible serine protease inhibitor, 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride, and refrozen. Serum concentrations of total ghrelin (LINCO Research, St. Charles, MO), acyl ghrelin (ALPCO Immunoassays, Salem, NH), des-acyl ghrelin (ALPCO Immunoassays), motilin (Phoenix Pharmaceuticals, Burlingame, CA), CCK (Phoenix Pharmaceuticals), and tumor necrosis factor (TNF)–α (Phoenix Pharmaceuticals) were determined with enzyme-linked immunosorbent assays. Hormone concentrations were measured in duplicate using the 4-hour or 6-hour blood samples.</p>
</sec>
<sec id="section7-0148607111413770">
<title>Statistical Analysis</title>
<p>A power analysis was not conducted as this was a post hoc assessment of existing data.<sup><xref ref-type="bibr" rid="bibr46-0148607111413770">46</xref>,<xref ref-type="bibr" rid="bibr47-0148607111413770">47</xref></sup> The primary outcome was the comparative assessment of the serum concentrations of acyl ghrelin, motilin, CCK, and the ratio of acyl ghrelin to des-acyl ghrelin in patients without intolerance to the baseline values obtained from those with intolerance. Statistical analyses of continuous data between patient groups with and without intolerance used the <italic>t</italic> test or Mann-Whitney <italic>U</italic> test for parametric data and nonparametric data, respectively. Statistical analyses comparing continuous data obtained after prokinetic therapy to baseline values used the paired <italic>t</italic> test or Wilcoxon signed-rank test for parametric data and nonparametric data, respectively. Secondary analyses tested for associations between hormone concentrations and inflammatory response and hormone concentrations and the pharmacokinetic parameters of gastric emptying obtained by the acetaminophen absorption model. Pearson product-moment correlation for parametric data or Spearman rank-order correlation for nonparametric data was used to determine if a relationship existed between hormone concentrations and TNF-α or the pharmacokinetic variables. All statistical analyses used SigmaStat (version 2.03; SPSS, an IBM Company, Chicago, IL). Statistical significance was defined as <italic>P</italic> &lt; .05. All data are reported as mean ± SD unless stated otherwise.</p>
</sec>
</sec>
<sec id="section8-0148607111413770" sec-type="results">
<title>Results</title>
<sec id="section9-0148607111413770">
<title>Patient and Nutrition Parameters</title>
<p>Ten and 20 patients were enrolled into the tolerant and intolerant groups, respectively. All patients were included in the final data analyses. Patient demographics and clinical statistics were similar between groups, except patients with tolerance tended to be heavier and were more likely to be female, although these were not statistically different (<xref ref-type="table" rid="table1-0148607111413770">Table 1</xref>). All patients included in the study had the head of their bed elevated to at least a 30° angle.</p>
<table-wrap id="table1-0148607111413770" position="float">
<label>Table 1.</label>
<caption>
<p>Patient and Nutrition-Related Variables<sup><xref ref-type="bibr" rid="bibr46-0148607111413770">46</xref></sup></p>
</caption>
<graphic alternate-form-of="table1-0148607111413770" xlink:href="10.1177_0148607111413770-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Characteristic</th>
<th align="center">Tolerant (n = 10)</th>
<th align="center">Intolerant (n = 20)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y, mean ± SD</td>
<td>56.3 ± 12.6</td>
<td>49.6 ± 11.6</td>
</tr>
<tr>
<td>Male, No. (%)</td>
<td>4 (40)</td>
<td>14 (70)</td>
</tr>
<tr>
<td>Weight, kg, mean ± SD</td>
<td>96.2 ± 37.0</td>
<td>76.2 ± 15.3</td>
</tr>
<tr>
<td>Body mass index, kg/m<sup>2</sup>, mean ± SD</td>
<td>34.2 ± 15.2</td>
<td>25.6 ± 5.3</td>
</tr>
<tr>
<td>APACHE III score, mean ± SD</td>
<td>67.7 ± 18.9</td>
<td>77.1 ± 24.9</td>
</tr>
<tr>
<td>ICU day enrolled, mean ± SD</td>
<td>7.6 ± 3.7</td>
<td>8.4 ± 4.4</td>
</tr>
<tr>
<td>Diabetic prior to admission, No. (%)</td>
<td>2 (20)</td>
<td>4 (20)</td>
</tr>
<tr>
<td>PUD/GERD prior to admission, No. (%)</td>
<td>2 (20)</td>
<td>4 (20)</td>
</tr>
<tr>
<td>Renal dysfunction, No. (%)</td>
<td>3 (30)</td>
<td>4 (20)</td>
</tr>
<tr>
<td colspan="3">Admission diagnosis, No. (%)</td>
</tr>
<tr>
<td> Sepsis</td>
<td>5 (50)</td>
<td>10 (50)</td>
</tr>
<tr>
<td> Pulmonary</td>
<td>3 (30)</td>
<td>6 (30)</td>
</tr>
<tr>
<td> Neurologic</td>
<td>1 (10)</td>
<td>3 (15)</td>
</tr>
<tr>
<td> Cardiac</td>
<td>1 (10)</td>
<td>1 (5)</td>
</tr>
<tr>
<td>Receiving opioid therapy at study entry, No. (%)</td>
<td>9 (90)</td>
<td>17 (85)</td>
</tr>
<tr>
<td>Time to enrollment after initiating enteral nutrition, h, mean ± SD</td>
<td>71.8 ± 25.9</td>
<td>70.5 ± 79.1</td>
</tr>
<tr>
<td>Goal caloric enteral rate, mL/h, mean ± SD</td>
<td>56.5 ± 8.4</td>
<td>64.3 ± 9.6</td>
</tr>
<tr>
<td>Enteral rate at time of enrollment, mL/h, mean ± SD</td>
<td>56.5 ± 8.4</td>
<td>36.4 ± 18.9<sup><xref ref-type="table-fn" rid="table-fn2-0148607111413770">a</xref></sup></td>
</tr>
<tr>
<td>Cumulative aspirated gastric residual volume for 24 hours before  enrollment, mL, mean ± SD</td>
<td>55.6 ± 55.9</td>
<td>620.6 ± 233.6<sup><xref ref-type="table-fn" rid="table-fn3-0148607111413770">b</xref></sup></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0148607111413770">
<p>APACHE, Acute Physiology and Chronic Health Evaluation; GERD, gastroesophageal reflux disease; ICU, intensive care unit; PUD, peptic ulcer disease. Body mass index calculated as weight in kg divided by height<sup>2</sup> in meters.</p>
</fn>
<fn id="table-fn2-0148607111413770">
<label>a</label>
<p><italic>P</italic> &lt; .001.</p>
</fn>
<fn id="table-fn3-0148607111413770">
<label>b</label>
<p><italic>P</italic> &lt; .0001.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Twenty-five (83.3%) patients were receiving Ultracal (Novartis Nutrition, Hopkins, MN) at the time of enrollment. Nutrition formulations were similar between groups.<sup><xref ref-type="bibr" rid="bibr46-0148607111413770">46</xref>,<xref ref-type="bibr" rid="bibr47-0148607111413770">47</xref></sup> Patients in the tolerant group demonstrated lower rates of gastric residual volumes over a 24-hour period prior to study enrollment, despite receiving EN at a higher rate than the intolerant group (<xref ref-type="table" rid="table1-0148607111413770">Table 1</xref>). Patients in both groups had been in the ICU for approximately 1 week and had been receiving EN for nearly 72 hours prior to enrollment.</p>
</sec>
<sec id="section10-0148607111413770">
<title>Gastric Emptying Parameters</title>
<p>Patients tolerating EN had greater C<sub>max</sub>, C<sub>60</sub>, and AUC<sub>60</sub> and shortened t<sub>max</sub> compared with patients intolerant to EN (<xref ref-type="table" rid="table2-0148607111413770">Table 2</xref>).<sup><xref ref-type="bibr" rid="bibr47-0148607111413770">47</xref></sup> All patients in the intolerant group were randomized to receive either erythromycin (n = 10) or metoclopramide (n = 10). After 4 doses, C<sub>max</sub>, C<sub>60</sub>, and AUC<sub>60</sub> increased and t<sub>max</sub> shortened (<xref ref-type="table" rid="table2-0148607111413770">Table 2</xref>).<sup><xref ref-type="bibr" rid="bibr46-0148607111413770">46</xref></sup> Erythromycin demonstrated slightly greater differences from baseline compared to metoclopramide.<sup><xref ref-type="bibr" rid="bibr46-0148607111413770">46</xref></sup> The volume of gastric residual decreased significantly with both prokinetic agents, whereas the rate of EN administration increased significantly.<sup><xref ref-type="bibr" rid="bibr46-0148607111413770">46</xref></sup></p>
<table-wrap id="table2-0148607111413770" position="float">
<label>Table 2.</label>
<caption>
<p>Gastric Emptying Parameters and Serum Concentrations of Gastrointestinal Hormones and TNF-α<sup><xref ref-type="bibr" rid="bibr46-0148607111413770">46</xref>,<xref ref-type="bibr" rid="bibr47-0148607111413770">47</xref></sup></p>
</caption>
<graphic alternate-form-of="table2-0148607111413770" xlink:href="10.1177_0148607111413770-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th/>
<th align="center" colspan="2">Intolerant (n = 20)</th>
</tr>
<tr>
<th align="left">Characteristic</th>
<th align="center">Tolerant (n = 10)</th>
<th align="center">Baseline</th>
<th align="center">Post-Prokinetic</th>
</tr>
</thead>
<tbody>
<tr>
<td>C<sub>max</sub>, mg/L</td>
<td>14.1 ± 7.3<sup><xref ref-type="table-fn" rid="table-fn5-0148607111413770">a</xref></sup></td>
<td>9.3 ± 5.2</td>
<td>15.3 ± 8.9<sup><xref ref-type="table-fn" rid="table-fn6-0148607111413770">b</xref></sup></td>
</tr>
<tr>
<td>C<sub>60</sub>, mg/L</td>
<td>9.6 ± 4.7<sup><xref ref-type="table-fn" rid="table-fn5-0148607111413770">a</xref></sup></td>
<td>6.1 ± 4.0</td>
<td>12.0 ± 6.0<sup><xref ref-type="table-fn" rid="table-fn7-0148607111413770">c</xref></sup></td>
</tr>
<tr>
<td>AUC<sub>60</sub>, mg/h/L</td>
<td>10.0 ± 6.0<sup><xref ref-type="table-fn" rid="table-fn6-0148607111413770">b</xref></sup></td>
<td>3.9 ± 2.8</td>
<td>10.9 ± 6.6<sup><xref ref-type="table-fn" rid="table-fn6-0148607111413770">b</xref></sup></td>
</tr>
<tr>
<td>t<sub>max</sub>, h</td>
<td>0.81 ± 0.61<sup><xref ref-type="table-fn" rid="table-fn7-0148607111413770">c</xref></sup></td>
<td>1.98 ± 1.26</td>
<td>1.07 ± 1.01<sup><xref ref-type="table-fn" rid="table-fn5-0148607111413770">a</xref></sup></td>
</tr>
<tr>
<td>Total ghrelin, pg/mL</td>
<td>285.1 ± 132.5</td>
<td>1324.8 ± 1204.6<sup><xref ref-type="table-fn" rid="table-fn8-0148607111413770">d</xref></sup></td>
<td>1463.8 ± 1273.1<sup><xref ref-type="table-fn" rid="table-fn8-0148607111413770">d</xref></sup></td>
</tr>
<tr>
<td>Acyl ghrelin, pg/mL</td>
<td>208.5 ± 186.9</td>
<td>70.5 ± 65.4<sup><xref ref-type="table-fn" rid="table-fn9-0148607111413770">e</xref></sup></td>
<td>43.4 ± 36.8<sup><xref ref-type="table-fn" rid="table-fn10-0148607111413770">f</xref></sup></td>
</tr>
<tr>
<td>Des-acyl ghrelin, pg/mL</td>
<td>90.7 ± 61.7</td>
<td>101.0 ± 87.0</td>
<td>95.0 ± 78.4</td>
</tr>
<tr>
<td>Acyl:des-acyl ratio</td>
<td>3.47 ± 3.21</td>
<td>1.11 ± 1.35<sup><xref ref-type="table-fn" rid="table-fn9-0148607111413770">e</xref></sup></td>
<td>0.95 ± 1.41<sup><xref ref-type="table-fn" rid="table-fn9-0148607111413770">e</xref></sup></td>
</tr>
<tr>
<td>Motilin, ng/mL</td>
<td>1.57 ± 0.77</td>
<td>1.58 ± 0.41</td>
<td>1.68 ± 0.47</td>
</tr>
<tr>
<td>Cholecystokinin, ng/mL</td>
<td>0.40 ± 0.64</td>
<td>0.24 ± 0.06</td>
<td>0.22 ± 0.06</td>
</tr>
<tr>
<td>TNF-α, pg/mL</td>
<td>74.9 ± 69.1</td>
<td>67.2 ± 43.5</td>
<td>51.4 ± 25.7</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-0148607111413770">
<p>Values presented as mean ± SD. AUC<sub>60</sub>, area under the concentration-time curve for 60 minutes; C<sub>60</sub>, concentration at 60 minutes; C<sub>max</sub>, peak concentration; t<sub>max</sub>, time to peak concentration; TNF, tumor necrosis factor. Prokinetic therapy consisted of metocloparmide 10 mg administered intravenously every 6 hours for 4 doses (n = 10) or erythromycin 250 mg intravenously administered intravenously every 6 hours for 4 doses (n = 10).<sup><xref ref-type="bibr" rid="bibr47-0148607111413770">47</xref></sup></p>
</fn>
<fn id="table-fn5-0148607111413770">
<label>a</label>
<p><italic>P</italic> &lt; .05 vs intolerant baseline.</p>
</fn>
<fn id="table-fn6-0148607111413770">
<label>b</label>
<p><italic>P</italic> &lt; .01 vs intolerant baseline.</p>
</fn>
<fn id="table-fn7-0148607111413770">
<label>c</label>
<p><italic>P</italic> &lt; .001 vs intolerant baseline.</p>
</fn>
<fn id="table-fn8-0148607111413770">
<label>d</label>
<p><italic>P</italic> &lt; .001 vs tolerant.</p>
</fn>
<fn id="table-fn9-0148607111413770">
<label>e</label>
<p><italic>P</italic> &lt; .05 vs tolerant.</p>
</fn>
<fn id="table-fn10-0148607111413770">
<label>f</label>
<p><italic>P</italic> &lt; .01 vs tolerant.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section11-0148607111413770">
<title>Concentrations of Gastrointestinal Hormones</title>
<p>Patients with intolerance demonstrated significantly higher concentrations of total ghrelin, lower concentrations of acyl ghrelin, and lower ratios of acyl ghrelin to des-acyl ghrelin compared to patients tolerating EN (<xref ref-type="table" rid="table2-0148607111413770">Table 2</xref>). These differences were independent of body weight, body mass index (BMI), sex, and previous 24-hour caloric intake. Serum concentrations of des-acyl ghrelin, motilin, and CCK were similar between groups. Hormone concentrations were similar before and after the administration of prokinetic agents (<xref ref-type="table" rid="table2-0148607111413770">Table 2</xref>) and between erythromycin and metoclopramide.</p>
</sec>
<sec id="section12-0148607111413770">
<title>Gastrointestinal Hormones, Gastric Emptying, and Inflammation</title>
<p>No associations were found between gastrointestinal hormone concentrations and the pharmacokinetic variables used to assess gastric emptying. TNF-α concentrations were similar between patients with tolerance and intolerance to EN and before and after prokinetic therapy (<xref ref-type="table" rid="table2-0148607111413770">Table 2</xref>). No associations were observed between serum concentrations of any gastrointestinal hormone and TNF-α.</p>
</sec>
</sec>
<sec id="section13-0148607111413770" sec-type="discussion">
<title>Discussion</title>
<p>Previous studies have demonstrated that CCK and PYY are increased in critical illness, and CCK may be further elevated when EN intolerance is present.<sup><xref ref-type="bibr" rid="bibr33-0148607111413770">33</xref>-<xref ref-type="bibr" rid="bibr36-0148607111413770">36</xref></sup> This study is the first to evaluate the serum concentrations of various ghrelin moieties and motilin in patients with and without EN intolerance and assess whether concentrations of these hormones change with prokinetic therapy. This study also explored possible associations between these hormones and gastric emptying or TNF-α. The key findings of this study are that compared to patients tolerating EN, patients with intolerance demonstrated (1) higher concentrations of total ghrelin and lower concentrations of acyl ghrelin; (2) lower ratios of acyl to des-acyl ghrelin, suggesting that the conversion of ghrelin to the active moiety may be impaired; and (3) similar concentrations of CCK and motilin. Other important findings include no apparent affect of prokinetic agents on the concentrations of these hormones and no associations between the concentrations of these hormones and gastric emptying or inflammation.</p>
<p>Ghrelin is a 28–amino acid peptide that was originally identified as an endogenous ligand for growth hormone secretagogue receptor 1a.<sup><xref ref-type="bibr" rid="bibr38-0148607111413770">38</xref>-<xref ref-type="bibr" rid="bibr42-0148607111413770">42</xref></sup> In addition to possessing strong growth hormone stimulating activity, ghrelin enhances appetite, increases energy stores, and decreases adipose utilization.<sup><xref ref-type="bibr" rid="bibr38-0148607111413770">38</xref>-<xref ref-type="bibr" rid="bibr42-0148607111413770">42</xref></sup> Ghrelin also stimulates gastric emptying by inducing the MMC, especially postprandially.<sup><xref ref-type="bibr" rid="bibr38-0148607111413770">38</xref>-<xref ref-type="bibr" rid="bibr42-0148607111413770">42</xref></sup> The greatest amount of secretion of circulating ghrelin (approximately 60%−90%) is by the oxyntic mucosal cells of the gastric epithelium. Substantially less generation occurs in the jejunum, ileum, colon, and cecum.<sup><xref ref-type="bibr" rid="bibr38-0148607111413770">38</xref>-<xref ref-type="bibr" rid="bibr42-0148607111413770">42</xref></sup> Although the majority of circulating ghrelin is nonacylated ghrelin (des-acyl ghrelin),<sup><xref ref-type="bibr" rid="bibr38-0148607111413770">38</xref>-<xref ref-type="bibr" rid="bibr42-0148607111413770">42</xref></sup> a unique posttranslational modification is essential for the biological activity of ghrelin. Esterification of the hydroxyl group of the third serine residue (Ser<sup><xref ref-type="bibr" rid="bibr3-0148607111413770">3</xref></sup>) by octanoic acid creates the active, acylated form of ghrelin.<sup><xref ref-type="bibr" rid="bibr38-0148607111413770">38</xref>-<xref ref-type="bibr" rid="bibr42-0148607111413770">42</xref></sup> Recently, ghrelin o-acyltransferase (GOAT) was identified as the enzyme responsible for converting des-acyl ghrelin to acyl ghrelin.<sup><xref ref-type="bibr" rid="bibr48-0148607111413770">48</xref></sup> The results of this study show that intolerance to gastric EN is associated with significantly lower serum concentrations of acyl ghrelin despite substantially higher total ghrelin expression. Moreover, the lower ratio of acyl to des-acyl ghrelin concentrations suggests that either patients with intolerance possess impaired ability to generate the active form of ghrelin or patients with tolerance have enhanced production of acyl ghrelin.<sup><xref ref-type="bibr" rid="bibr48-0148607111413770">48</xref></sup> This may be the result of altered GOAT activity or expression because GOAT is the only known enzyme responsible for the conversion of des-acyl ghrelin to its active form and is highly co-localized within the same gastric mucosal cells that contain ghrelin.<sup><xref ref-type="bibr" rid="bibr38-0148607111413770">38</xref>-<xref ref-type="bibr" rid="bibr42-0148607111413770">42</xref>,<xref ref-type="bibr" rid="bibr48-0148607111413770">48</xref></sup> Although impaired elimination associated with critical illness may partly explain some of the variation observed in serum concentrations, all these hormones possess short half-lives. The higher serum concentrations of total ghrelin in patients with intolerance may be the result of enhanced ghrelin production in the relatively few gastrointestinal cells that do not coexpress GOAT.<sup><xref ref-type="bibr" rid="bibr48-0148607111413770">48</xref></sup> Another plausible explanation for the increased concentrations of total ghrelin in the intolerant group may be due to altered GOAT function generating other forms of ghrelin other than acyl or des-acyl ghrelin.<sup><xref ref-type="bibr" rid="bibr48-0148607111413770">48</xref></sup> Long-term fasting reduces ghrelin acylation and activation but not total ghrelin secretion, possibly due to reduced dietary octanoate that is necessary for GOAT acylation of ghrelin.<sup><xref ref-type="bibr" rid="bibr48-0148607111413770">48</xref></sup> Therefore, patients with intolerance may not consume sufficient amounts of octanoate to maintain the functionality of GOAT. This study did not find an association between the concentrations of various ghrelin moieties and caloric intake. Studies have shown that obesity may be related to increased ghrelin production.<sup><xref ref-type="bibr" rid="bibr38-0148607111413770">38</xref>-<xref ref-type="bibr" rid="bibr42-0148607111413770">42</xref></sup></p>
<p>This study found lower ghrelin concentrations in patients with tolerance to EN despite this group being substantially heavier and having higher BMI values than those with intolerance. This suggests that body weight and BMI did not contribute to the observed differences. Similarly, the short-term use of prokinetic agents was not associated with changes in the concentrations of ghrelin or its active and inactive forms, suggesting that neither agent affects these hormones. However, the 24-hour time period of prokinetic therapy may be too short to observe substantial changes in ghrelin expression. The results of many studies have found higher total ghrelin serum concentrations in various populations, including acute and chronic liver dysfunction of different etiologies, generalized critical illness, acute pancreatitis, dialysis dependent, cystic fibrosis, and acute coronary syndrome.<sup><xref ref-type="bibr" rid="bibr43-0148607111413770">43</xref>-<xref ref-type="bibr" rid="bibr45-0148607111413770">45</xref>,<xref ref-type="bibr" rid="bibr49-0148607111413770">49</xref>-<xref ref-type="bibr" rid="bibr54-0148607111413770">54</xref></sup> Other studies of critically ill patients showed lower total ghrelin concentrations.<sup><xref ref-type="bibr" rid="bibr55-0148607111413770">55</xref>,<xref ref-type="bibr" rid="bibr56-0148607111413770">56</xref></sup> Unfortunately, few of these studies investigated the relative production of different forms of ghrelin. The values of total ghrelin obtained in this study are within the range of concentrations reported in other patient populations.<sup><xref ref-type="bibr" rid="bibr43-0148607111413770">43</xref>-<xref ref-type="bibr" rid="bibr45-0148607111413770">45</xref>,<xref ref-type="bibr" rid="bibr49-0148607111413770">49</xref>-<xref ref-type="bibr" rid="bibr56-0148607111413770">56</xref></sup> However, the concentrations of acyl ghrelin measured in the intolerant group are substantially lower than the value measured in patients with liver cirrhosis.<sup><xref ref-type="bibr" rid="bibr51-0148607111413770">51</xref></sup> Of note, the expression of ghrelin relative to critical illness and the resolution of injury are not well studied, so altered concentrations in this study may be related to the phases of illness.</p>
<p>Motilin is a 22–amino acid peptide that is synthesized by endocrine cells located in the duodeno-jejunal mucosa.<sup><xref ref-type="bibr" rid="bibr37-0148607111413770">37</xref>,<xref ref-type="bibr" rid="bibr38-0148607111413770">38</xref></sup> Like ghrelin, motilin stimulates gastric MMC.<sup><xref ref-type="bibr" rid="bibr37-0148607111413770">37</xref>,<xref ref-type="bibr" rid="bibr38-0148607111413770">38</xref></sup> Precursors of the 2 hormones share up to 50% similarity in their amino acid sequences, and they innervate the same family of G-coupled protein receptors, which again share approximately 50% of their overall amino acid sequence identity.<sup><xref ref-type="bibr" rid="bibr37-0148607111413770">37</xref>,<xref ref-type="bibr" rid="bibr38-0148607111413770">38</xref></sup> Results from this study demonstrate similar motilin concentrations in patients tolerant and intolerant to gastric EN. This may relate to the fact that unlike ghrelin, motilin is produced as an active form in the proximal portion of the small intestine. Although critically ill patients frequently possess abnormal intestinal motility, the patients enrolled in this study were required only to display impaired gastric emptying as measured by the volume of gastric aspirate.<sup><xref ref-type="bibr" rid="bibr57-0148607111413770">57</xref></sup> Therefore, intestinal function, including motilin production, may not differ substantially between the 2 groups. Similar to ghrelin, neither prokinetic agent altered serum motilin concentrations. Of note, the motilin concentrations obtained in this study are approximately 0.50–1.50 ng/mL lower than those measured in a study of burn patients receiving either enteral or parenteral nutrition.<sup><xref ref-type="bibr" rid="bibr58-0148607111413770">58</xref></sup></p>
<p>CCK is produced as a mixture of peptides by a distinct group of endocrine cells (I cells) distributed throughout the mucosa of the duodenum and upper jejunum.<sup><xref ref-type="bibr" rid="bibr9-0148607111413770">9</xref>-<xref ref-type="bibr" rid="bibr11-0148607111413770">11</xref></sup> Stimulation of the CCK-1 receptor slows gastric and colonic emptying. The results of this study did not demonstrate differences in the concentrations of CCK in patients tolerant and intolerant to gastric EN, although the concentrations were substantially higher in patients with tolerance. This is contradictory to the inhibitory action of CCK on gastric motility but may reflect enhanced production associated with the greater caloric intake in this group. In contrast, Nguyen et al<sup><xref ref-type="bibr" rid="bibr35-0148607111413770">35</xref>,<xref ref-type="bibr" rid="bibr36-0148607111413770">36</xref></sup> found that fasting and nutrient-stimulated CCK generation are greater in critically ill patients than in healthy volunteers and that the highest CCK response occurred in those with intolerance. Recently, it has been shown that ghrelin and CCK negatively influence the synthesis of one another, which may explain the relatively low total ghrelin concentrations and high CCK concentrations in patients tolerating EN compared with those with intolerance. The results of animal models indicate that the activity of acyl ghrelin may be heightened by CCK, which may further explain the elevated CCK concentrations in the patients tolerating EN in this study.<sup><xref ref-type="bibr" rid="bibr39-0148607111413770">39</xref>-<xref ref-type="bibr" rid="bibr42-0148607111413770">42</xref></sup> Similar to ghrelin and motilin, the use of prokinetic agents did not affect the expression of CCK. It is difficult to compare CCK concentrations obtained in this study with those measured in other studies as the commonly reported unit is pmol/L, and conversion to ng/mL is dependent on the molecular weights of the various CCK peptides that were inconsistently assessed across studies.</p>
<p>Although patients with intolerance to gastric EN demonstrated delayed gastric emptying using the acetaminophen absorption model, neither ghrelin nor motilin concentrations were associated with any pharmacokinetic parameter representing gastric emptying. This is somewhat surprising because the expression of ghrelin varied between patients tolerant and intolerant to EN. The relationship between these hormones and gastric emptying in critical illness requires further investigation. Both ghrelin and motilin possess anti-inflammatory activity, and inflammation may suppress the expression of these hormones.<sup><xref ref-type="bibr" rid="bibr39-0148607111413770">39</xref>-<xref ref-type="bibr" rid="bibr42-0148607111413770">42</xref></sup> Concentrations of TNF-α were similar across all study groups. An association between serum concentrations of TNF-α and these hormones was not evident in this study; however, the substantial variation in TNF-α concentrations and the diverse but limited number of patients may have limited the ability to detect an association. Despite evidence that inflammation suppresses gastrointestinal motility, the pharmacokinetic parameters of gastric emptying were not associated with serum concentrations of TNF-α. The role of other proinflammatory cytokines, such as interleukin (IL)−1b or IL-6, in the pathogenesis of gastroparesis related to critical illness requires further elucidation. Activation of the proinflammatory mediators IL-8 and nuclear factor κB has been directly linked to ghrelin expression, and these may better represent the interaction between inflammation and the gastrointestinal hormones.<sup><xref ref-type="bibr" rid="bibr39-0148607111413770">39</xref>-<xref ref-type="bibr" rid="bibr42-0148607111413770">42</xref></sup></p>
<p>This study is not without limitations. The post hoc assessment of few patients with diverse diagnoses provides results that are speculative rather than definitive as the design of the original studies did not incorporate measurements of these hormones.<sup><xref ref-type="bibr" rid="bibr48-0148607111413770">48</xref>,<xref ref-type="bibr" rid="bibr49-0148607111413770">49</xref></sup> The small number of patients may negate the demonstration of differences (eg, CCK concentrations) or associations (eg, TNF-α and hormone concentrations). Alternatively, differences may be evident that were driven by a few patients. In addition, ghrelin undergoes rapid degradation at room temperature and requires stabilization with protease inhibition. All serum samples were frozen at −80°C, but stabilization did not occur until samples were initially thawed for acetaminophen measurement. Therefore, the results of this study should be considered hypothesis generating and need to be validated. Gastric residual volume is only a surrogate marker of delayed gastric emptying in critically ill patients. The volume that represents intolerance is controversial,<sup><xref ref-type="bibr" rid="bibr28-0148607111413770">28</xref>-<xref ref-type="bibr" rid="bibr30-0148607111413770">30</xref>,<xref ref-type="bibr" rid="bibr59-0148607111413770">59</xref>-<xref ref-type="bibr" rid="bibr67-0148607111413770">67</xref></sup> but most guidelines define intolerance as residual volumes of 250–500 mL.<sup><xref ref-type="bibr" rid="bibr1-0148607111413770">1</xref>-<xref ref-type="bibr" rid="bibr4-0148607111413770">4</xref></sup> Although the inclusion criterion of this study defined intolerance as a single gastric residual volume &gt;150 mL, aspirate volumes were greater in general (<xref ref-type="table" rid="table2-0148607111413770">Table 2</xref>). In addition, those with intolerance displayed significantly impaired gastric emptying.<sup><xref ref-type="bibr" rid="bibr48-0148607111413770">48</xref></sup> At present, these results are hypothesis generating and should be viewed as a signal until confirmed in a prospective manner using higher thresholds for gastric residual volumes. The expression of these hormones, especially ghrelin, is affected by factors such as body weight, presence of diabetes, and satiation. Although those with intolerance differed substantially in body weight, BMI, and caloric intake from those tolerating gastric EN, additional analyses showed no effects of these differences. Last, other hormones, such as peptide YY, that influence gastric motility were not assessed.</p>
</sec>
<sec id="section14-0148607111413770" sec-type="conclusions">
<title>Conclusions</title>
<p>The concentrations of various ghrelin moieties differ in patients not tolerating gastric EN. Diminished acyl ghrelin may contribute to gastric hypomotility and feeding intolerance. Intolerance is not associated with altered concentrations of other hormones. Gastrointestinal hormone concentrations are not influenced by short-term prokinetic therapy.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p>Financial disclosure: This study was supported by the Society of Critical Care Medicine/Bayer/Joseph F. Dasta Critical Care Pharmacy Outcomes Research Grant.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0148607111413770">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McClave</surname><given-names>SA</given-names></name>
<name><surname>DeMeo</surname><given-names>MT</given-names></name>
<name><surname>DeLegge</surname></name>
<etal/>
</person-group>. <article-title>North American Summit on aspiration in the critically ill patient: consensus statement</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2002</year>;<volume>26</volume>(<issue>6</issue>)(<supplement>suppl</supplement>):<fpage>S80</fpage>-<lpage>S85</lpage>.</citation>
</ref>
<ref id="bibr2-0148607111413770">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kreymann</surname><given-names>KG</given-names></name>
<name><surname>Berger</surname><given-names>MM</given-names></name>
<name><surname>Deutz</surname><given-names>NE</given-names></name>
<etal/>
</person-group>. <article-title>ESPEN guidelines on enteral nutrition: intensive nutrition</article-title>. <source>Clin Nutr</source>. <year>2006</year>;<volume>25</volume>:<fpage>210</fpage>-<lpage>223</lpage>.</citation>
</ref>
<ref id="bibr3-0148607111413770">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stroud</surname><given-names>M</given-names></name>
<name><surname>Duncan</surname><given-names>H</given-names></name>
<name><surname>Nightingale</surname><given-names>J</given-names></name>
</person-group>; <collab>British Society of Gastroenterology</collab>. <article-title>Guidelines for enteral feeding in adult hospital patients</article-title>. <source>Gut</source>. <year>2003</year>;<volume>52</volume>(<issue>suppl 7</issue>):<fpage>vii7</fpage>-<lpage>vii12</lpage>.</citation>
</ref>
<ref id="bibr4-0148607111413770">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Heyland</surname><given-names>DK</given-names></name>
<name><surname>Dhaliwal</surname><given-names>R</given-names></name>
<name><surname>Drover</surname><given-names>JW</given-names></name>
</person-group>; <collab>Canadian Critical Care Clinical Practice Guidelines Committee</collab>. <article-title>Canadian clinical practice guidelines for nutrition support in mechanically ventilated, critically ill adult patients</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2003</year>;<volume>27</volume>:<fpage>355</fpage>-<lpage>373</lpage>.</citation>
</ref>
<ref id="bibr5-0148607111413770">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kompan</surname><given-names>L</given-names></name>
<name><surname>Kremzar</surname><given-names>B</given-names></name>
<name><surname>Gadzijev</surname><given-names>E</given-names></name>
<name><surname>Prosek</surname><given-names>M</given-names></name>
</person-group>. <article-title>Effects of early enteral nutrition on intestinal permeability and the development of multiple organ failure after multiple injury</article-title>. <source>Intensive Care Med</source>. <year>1999</year>;<volume>25</volume>:<fpage>157</fpage>-<lpage>161</lpage>.</citation>
</ref>
<ref id="bibr6-0148607111413770">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Doig</surname><given-names>GS</given-names></name>
<name><surname>Heighes</surname><given-names>PT</given-names></name>
<name><surname>Simpson</surname><given-names>F</given-names></name>
<name><surname>Sweetman</surname><given-names>EA</given-names></name>
<name><surname>Davies</surname><given-names>AR</given-names></name>
</person-group>. <article-title>Early enteral nutrition, provided within 24 h of injury or intensive care unit admission, significantly reduces mortality in critically ill patients: a meta-analysis of randomised controlled trials</article-title>. <source>Intensive Care Med</source>. <year>2009</year>;<volume>35</volume>:<fpage>2018</fpage>-<lpage>2027</lpage>.</citation>
</ref>
<ref id="bibr7-0148607111413770">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Marik</surname><given-names>PE</given-names></name>
<name><surname>Zaloga</surname><given-names>GP</given-names></name>
</person-group>. <article-title>Early enteral nutrition in acutely ill patients: a systematic review</article-title>. <source>Crit Care Med</source>. <year>2001</year>;<volume>26</volume>:<fpage>2264</fpage>-<lpage>2270</lpage>.</citation>
</ref>
<ref id="bibr8-0148607111413770">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Artinian</surname><given-names>V</given-names></name>
<name><surname>Krayem</surname><given-names>H</given-names></name>
<name><surname>DiGiovine</surname><given-names>B</given-names></name>
</person-group>. <article-title>Effects of early enteral feeding on the outcomes of critically ill mechanically ventilated medical patients</article-title>. <source>Chest</source>. <year>2006</year>;<volume>129</volume>:<fpage>960</fpage>-<lpage>967</lpage>.</citation>
</ref>
<ref id="bibr9-0148607111413770">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chapman</surname><given-names>MJ</given-names></name>
<name><surname>Nguyen</surname><given-names>NQ</given-names></name>
<name><surname>Fraser</surname><given-names>RJ</given-names></name>
</person-group>. <article-title>Gastrointestinal motility and prokinetics in the critically ill</article-title>. <source>Curr Opin Crit Care</source>. <year>2007</year>;<volume>13</volume>:<fpage>187</fpage>-<lpage>194</lpage>.</citation>
</ref>
<ref id="bibr10-0148607111413770">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fruhwald</surname><given-names>S</given-names></name>
<name><surname>Holzer</surname><given-names>P</given-names></name>
<name><surname>Metzler</surname><given-names>H</given-names></name>
</person-group>. <article-title>Intestinal motility disturbances in intensive care patients: pathogenesis and clinical impact</article-title>. <source>Intensive Care Med</source>. <year>2007</year>;<volume>33</volume>:<fpage>36</fpage>-<lpage>44</lpage>.</citation>
</ref>
<ref id="bibr11-0148607111413770">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Deane</surname><given-names>A</given-names></name>
<name><surname>Chapman</surname><given-names>MJ</given-names></name>
<name><surname>Fraser</surname><given-names>RJ</given-names></name>
<name><surname>Bryant</surname><given-names>LK</given-names></name>
<name><surname>Burgstad</surname><given-names>C</given-names></name>
<name><surname>Nguyen</surname><given-names>NQ</given-names></name>
</person-group>. <article-title>Mechanisms underlying feed intolerance in the critically ill: implications for treatment</article-title>. <source>World J Gastroenterol</source>. <year>2007</year>;<volume>13</volume>:<fpage>3909</fpage>-<lpage>3917</lpage>.</citation>
</ref>
<ref id="bibr12-0148607111413770">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mutlu</surname><given-names>GM</given-names></name>
<name><surname>Mutlu</surname><given-names>EA</given-names></name>
<name><surname>Factor</surname><given-names>P</given-names></name>
</person-group>. <article-title>GI complications in patients receiving mechanical ventilation</article-title>. <source>Chest</source>. <year>2001</year>;<volume>119</volume>:<fpage>1222</fpage>-<lpage>1241</lpage>.</citation>
</ref>
<ref id="bibr13-0148607111413770">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dive</surname><given-names>A</given-names></name>
<name><surname>Moulart</surname><given-names>M</given-names></name>
<name><surname>Jonard</surname><given-names>P</given-names></name>
<name><surname>Jamart</surname><given-names>J</given-names></name>
<name><surname>Mahieu</surname><given-names>P</given-names></name>
</person-group>. <article-title>Gastroduodenal motility in mechanically ventilated critically ill patients: a manometric study</article-title>. <source>Crit Care Med</source>. <year>1994</year>;<volume>22</volume>:<fpage>441</fpage>-<lpage>447</lpage>.</citation>
</ref>
<ref id="bibr14-0148607111413770">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Heyland</surname><given-names>DK</given-names></name>
<name><surname>Tougas</surname><given-names>G</given-names></name>
<name><surname>King</surname><given-names>D</given-names></name>
<name><surname>Cook</surname><given-names>DJ</given-names></name>
</person-group>. <article-title>Impaired gastric emptying in mechanically ventilated, critically ill patients</article-title>. <source>Intensive Care Med</source>. <year>1996</year>;<volume>22</volume>:<fpage>1339</fpage>-<lpage>1344</lpage>.</citation>
</ref>
<ref id="bibr15-0148607111413770">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ritz</surname><given-names>MA</given-names></name>
<name><surname>Fraser</surname><given-names>R</given-names></name>
<name><surname>Edwards</surname><given-names>N</given-names></name>
<etal/>
</person-group>. <article-title>Delayed gastric emptying in ventilated critically ill patients: measurement by 13 C-octanoic acid breath test</article-title>. <source>Crit Care Med</source>. <year>2001</year>;<volume>29</volume>:<fpage>1744</fpage>-<lpage>1749</lpage>.</citation>
</ref>
<ref id="bibr16-0148607111413770">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Montejo</surname><given-names>JC</given-names></name>
</person-group>; <collab>for the Nutritional and Metabolic Working Group of the Spanish Society of Intensive Care Medicine and Coronary Units</collab>. <article-title>Enteral nutrition-related gastrointestinal complications in critically ill patients: a multicenter study</article-title>. <source>Crit Care Med</source>. <year>1999</year>;<volume>27</volume>:<fpage>1447</fpage>-<lpage>1453</lpage>.</citation>
</ref>
<ref id="bibr17-0148607111413770">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chang</surname><given-names>RWS</given-names></name>
<name><surname>Jacobs</surname><given-names>S</given-names></name>
<name><surname>Lee</surname><given-names>B</given-names></name>
</person-group>. <article-title>Gastrointestinal dysfunction among intensive care unit patients</article-title>. <source>Crit Care Med</source>. <year>1987</year>;<volume>15</volume>:<fpage>909</fpage>-<lpage>914</lpage>.</citation>
</ref>
<ref id="bibr18-0148607111413770">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Heyland</surname><given-names>D</given-names></name>
<name><surname>Cook</surname><given-names>DJ</given-names></name>
<name><surname>Winder</surname><given-names>B</given-names></name>
<name><surname>Brylowski</surname><given-names>L</given-names></name>
<name><surname>Van deMark</surname><given-names>H</given-names></name>
<name><surname>Guyatt</surname><given-names>G</given-names></name>
</person-group>. <article-title>Enteral nutrition in the critically ill patient: a prospective survey</article-title>. <source>Crit Care Med</source>. <year>1995</year>;<volume>23</volume>:<fpage>1055</fpage>-<lpage>1060</lpage>.</citation>
</ref>
<ref id="bibr19-0148607111413770">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Binnekade</surname><given-names>JM</given-names></name>
<name><surname>Tepaske</surname><given-names>R</given-names></name>
<name><surname>Bruynzeel</surname><given-names>P</given-names></name>
<name><surname>Mathus-Vliegen</surname><given-names>EM</given-names></name>
<name><surname>deHann</surname><given-names>RJ</given-names></name>
</person-group>. <article-title>Daily enteral feeding practice on the ICU: attainment of goals and interfering factors</article-title>. <source>Crit Care</source>. <year>2005</year>;<volume>9</volume>:<fpage>R218</fpage>-<lpage>R225</lpage>.</citation>
</ref>
<ref id="bibr20-0148607111413770">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Adam</surname><given-names>S</given-names></name>
<name><surname>Batson</surname><given-names>S</given-names></name>
</person-group>. <article-title>A study of problems associated with the delivery of enteral feed in critically ill patients in five ICUs in the UK</article-title>. <source>Intensive Care Med</source>. <year>1997</year>;<volume>23</volume>:<fpage>261</fpage>-<lpage>266</lpage>.</citation>
</ref>
<ref id="bibr21-0148607111413770">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McClave</surname><given-names>SA</given-names></name>
<name><surname>Sexton</surname><given-names>LK</given-names></name>
<name><surname>Spain</surname><given-names>DA</given-names></name>
<etal/>
</person-group>. <article-title>Enteral tube feeding in the intensive care unit: factors impeding adequate delivery</article-title>. <source>Crit Care Med</source>. <year>1999</year>;<volume>27</volume>:<fpage>1252</fpage>-<lpage>1256</lpage>.</citation>
</ref>
<ref id="bibr22-0148607111413770">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jones</surname><given-names>C</given-names></name>
<name><surname>Griffiths</surname><given-names>RD</given-names></name>
<name><surname>Macmillan</surname><given-names>RR</given-names></name>
<name><surname>Harris</surname><given-names>C</given-names></name>
<name><surname>Atherton</surname><given-names>ST</given-names></name>
<name><surname>Nee</surname><given-names>P</given-names></name>
</person-group>. <article-title>Difficulties achieving nasogastric feeding targets [abstract]</article-title>. <source>Intensive Care Med</source>. <year>1996</year>;<volume>22</volume>(<issue>suppl 3</issue>):<fpage>S345</fpage>.</citation>
</ref>
<ref id="bibr23-0148607111413770">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Heyland</surname><given-names>DK</given-names></name>
<name><surname>Dhaliwal</surname><given-names>R</given-names></name>
<name><surname>Day</surname><given-names>A</given-names></name>
<name><surname>Jain</surname><given-names>M</given-names></name>
<name><surname>Drover</surname><given-names>J</given-names></name>
</person-group>. <article-title>Validation of the Canadian clinical practice guidelines for nutrition support in mechanically ventilated, critically ill adult patients: results of a prospective observational study</article-title>. <source>Crit Care Med</source>. <year>2004</year>;<volume>32</volume>:<fpage>2260</fpage>-<lpage>2266</lpage>.</citation>
</ref>
<ref id="bibr24-0148607111413770">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Heyland</surname><given-names>DK</given-names></name>
<name><surname>Schroter-Noppe</surname><given-names>D</given-names></name>
<name><surname>Drover</surname><given-names>JW</given-names></name>
<etal/>
</person-group>. <article-title>Nutrition support in the critical care setting: current practice in Canadian ICUs—opportunities for improvement?</article-title> <source>JPEN J Parenter Enteral Nutr</source>. <year>2003</year>;<volume>27</volume>:<fpage>74</fpage>-<lpage>83</lpage>.</citation>
</ref>
<ref id="bibr25-0148607111413770">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bosscha</surname><given-names>K</given-names></name>
<name><surname>Nieuwenhuijs</surname><given-names>VB</given-names></name>
<name><surname>Vos</surname><given-names>A</given-names></name>
<name><surname>Samsom</surname><given-names>M</given-names></name>
<name><surname>Roelofs</surname><given-names>JM</given-names></name>
<name><surname>Akkermans</surname><given-names>LM</given-names></name>
</person-group>. <article-title>Gastrointestinal motility and gastric tube feeding in mechanically ventilated patients</article-title>. <source>Crit Care Med</source>. <year>1998</year>;<volume>26</volume>(<issue>9</issue>):<fpage>1510</fpage>-<lpage>1517</lpage>.</citation>
</ref>
<ref id="bibr26-0148607111413770">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mentec</surname><given-names>H</given-names></name>
<name><surname>Dupont</surname><given-names>H</given-names></name>
<name><surname>Bocchetti</surname><given-names>M</given-names></name>
<name><surname>Cani</surname><given-names>P</given-names></name>
<name><surname>Ponche</surname><given-names>F</given-names></name>
<name><surname>Bleichner</surname><given-names>G</given-names></name>
</person-group>. <article-title>Upper digestive intolerance during enteral nutrition in critically ill patients: frequency, risk factors, and complications</article-title>. <source>Crit Care Med</source>. <year>2001</year>;<volume>29</volume>:<fpage>1955</fpage>-<lpage>1961</lpage>.</citation>
</ref>
<ref id="bibr27-0148607111413770">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Inglis</surname><given-names>TJ</given-names></name>
<name><surname>Sherratt</surname><given-names>MJ</given-names></name>
<name><surname>Sproat</surname><given-names>LJ</given-names></name>
<name><surname>Gibson</surname><given-names>JS</given-names></name>
<name><surname>Hawkey</surname><given-names>PM</given-names></name>
</person-group>. <article-title>Gastroduodenal dysfunction and bacterial colonisation of the ventilated lung</article-title>. <source>Lancet</source>. <year>1993</year>;<volume>341</volume>:<fpage>911</fpage>-<lpage>913</lpage>.</citation>
</ref>
<ref id="bibr28-0148607111413770">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kazi</surname><given-names>N</given-names></name>
<name><surname>Mobarhan</surname><given-names>S</given-names></name>
</person-group>. <article-title>Enteral feeding associated gastroesophageal reflux and aspiration pneumonia: a review</article-title>. <source>Nutr Rev</source>. <year>1996</year>;<volume>54</volume>:<fpage>324</fpage>-<lpage>328</lpage>.</citation>
</ref>
<ref id="bibr29-0148607111413770">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>MacLaren</surname><given-names>R</given-names></name>
</person-group>. <article-title>Intolerance to intragastric enteral nutrition in critically ill patients: complications and management</article-title>. <source>Pharmacotherapy</source>. <year>2000</year>;<volume>20</volume>:<fpage>1486</fpage>-<lpage>1498</lpage>.</citation>
</ref>
<ref id="bibr30-0148607111413770">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Metheny</surname><given-names>NA</given-names></name>
<name><surname>Schallom</surname><given-names>ME</given-names></name>
<name><surname>Edwards</surname><given-names>SJ</given-names></name>
</person-group>. <article-title>Effect of gastrointestinal motility and feeding tube site on aspiration risk in critically ill patients: a review</article-title>. <source>Heart Lung</source>. <year>2004</year>;<volume>33</volume>:<fpage>131</fpage>-<lpage>145</lpage>.</citation>
</ref>
<ref id="bibr31-0148607111413770">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dodek</surname><given-names>P</given-names></name>
<name><surname>Keenan</surname><given-names>S</given-names></name>
<name><surname>Cook</surname><given-names>D</given-names></name>
<etal/>
</person-group>; <collab>Canadian Critical Care Trials Group; Canadian Critical Care Society</collab>. <article-title>Evidence-based clinical practice guideline for the prevention of ventilator-associated pneumonia</article-title>. <source>Ann Intern Med</source>. <year>2004</year>;<volume>141</volume>:<fpage>305</fpage>-<lpage>313</lpage>.</citation>
</ref>
<ref id="bibr32-0148607111413770">
<label>32.</label>
<citation citation-type="journal">
<collab>American Thoracic Society, Infectious Diseases Society of America</collab>. <article-title>Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia</article-title>. <source>Am J Respir Crit Care Med</source>. <year>2005</year>;<volume>171</volume>:<fpage>388</fpage>-<lpage>416</lpage>.</citation>
</ref>
<ref id="bibr33-0148607111413770">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nguyen</surname><given-names>NQ</given-names></name>
<name><surname>Fraser</surname><given-names>RJ</given-names></name>
<name><surname>Chapman</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Fasting and nutrient-stimulated plasma peptide-YY levels are elevated in critical illness, and associated with feed intolerance: an observational, controlled study</article-title>. <source>Crit Care</source>. <year>2006</year>;<volume>10</volume>:<fpage>R175</fpage>-<lpage>R184</lpage>.</citation>
</ref>
<ref id="bibr34-0148607111413770">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nguyen</surname><given-names>NQ</given-names></name>
<name><surname>Fraser</surname><given-names>RJ</given-names></name>
<name><surname>Bryant</surname><given-names>LK</given-names></name>
<etal/>
</person-group>. <article-title>The impact of delaying enteral feeding on gastric emptying, plasma cholecystokinin, and peptide YY concentrations in critically ill patients</article-title>. <source>Crit Care Med</source>. <year>2008</year>;<volume>26</volume>:<fpage>1469</fpage>-<lpage>1474</lpage>.</citation>
</ref>
<ref id="bibr35-0148607111413770">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nguyen</surname><given-names>NQ</given-names></name>
<name><surname>Fraser</surname><given-names>RJ</given-names></name>
<name><surname>Bryant</surname><given-names>LK</given-names></name>
<etal/>
</person-group>. <article-title>The relationship between gastric emptying, plasma cholecystokinin, and peptide YY in critically ill patients</article-title>. <source>Crit Care</source>. <year>2007</year>;<volume>11</volume>:<fpage>R132</fpage>-<lpage>R140</lpage>.</citation>
</ref>
<ref id="bibr36-0148607111413770">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nguyen</surname><given-names>NQ</given-names></name>
<name><surname>Fraser</surname><given-names>RJ</given-names></name>
<name><surname>Chapman</surname><given-names>MJ</given-names></name>
<etal/>
</person-group>. <article-title>Feed intolerance in critical illness is associated with increased basal and nutrient-stimulated plasma cholecystokinin concentrations</article-title>. <source>Crit Care Med</source>. <year>2007</year>;<volume>35</volume>:<fpage>82</fpage>-<lpage>88</lpage>.</citation>
</ref>
<ref id="bibr37-0148607111413770">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>De Smet</surname><given-names>B</given-names></name>
<name><surname>Mitselos</surname><given-names>A</given-names></name>
<name><surname>Depoortere</surname><given-names>I</given-names></name>
</person-group>. <article-title>Motilin and ghrelin as prokinetic drug targets</article-title>. <source>Pharmacol Ther</source>. <year>2009</year>;<volume>123</volume>:<fpage>207</fpage>-<lpage>223</lpage>.</citation>
</ref>
<ref id="bibr38-0148607111413770">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ohno</surname><given-names>T</given-names></name>
<name><surname>Mochiki</surname><given-names>E</given-names></name>
<name><surname>Kuwano</surname><given-names>H</given-names></name>
</person-group>. <article-title>The roles of motilin and ghrelin in gastrointestinal motility</article-title>. <source>Int J Pept</source>. <year>2010</year>;<volume>2010</volume>:<fpage>1</fpage>-<lpage>6</lpage>.</citation>
</ref>
<ref id="bibr39-0148607111413770">
<label>39.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Camilleri</surname><given-names>M</given-names></name>
<name><surname>Papathanasopoulos</surname><given-names>A</given-names></name>
<name><surname>Odunsi</surname><given-names>ST</given-names></name>
</person-group>. <article-title>Actions and therapeutic pathways of ghrelin for gastrointestinal disorders</article-title>. <source>Nat Rev Gastroenterol Hepatol</source>. <year>2009</year>;<volume>6</volume>:<fpage>343</fpage>-<lpage>352</lpage>.</citation>
</ref>
<ref id="bibr40-0148607111413770">
<label>40.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chen</surname><given-names>CY</given-names></name>
<name><surname>Asakawa</surname><given-names>A</given-names></name>
<name><surname>Fujimiya</surname><given-names>M</given-names></name>
<name><surname>Lee</surname><given-names>SD</given-names></name>
<name><surname>Inui</surname><given-names>A</given-names></name>
</person-group>. <article-title>Ghrelin gene products and the regulation of food intake and gut motility</article-title>. <source>Pharmacol Rev</source>. <year>2009</year>;<volume>61</volume>:<fpage>430</fpage>-<lpage>481</lpage>.</citation>
</ref>
<ref id="bibr41-0148607111413770">
<label>41.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kageyama</surname><given-names>H</given-names></name>
<name><surname>Takenoya</surname><given-names>F</given-names></name>
<name><surname>Shiba</surname><given-names>K</given-names></name>
<name><surname>Shioda</surname><given-names>S</given-names></name>
</person-group>. <article-title>Neuronal circuits involving ghrelin in the hypothalamus-mediated regulation of feeding</article-title>. <source>Neuropeptides</source>. <year>2010</year>;<volume>44</volume>:<fpage>133</fpage>-<lpage>138</lpage>.</citation>
</ref>
<ref id="bibr42-0148607111413770">
<label>42.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ueno</surname><given-names>H</given-names></name>
<name><surname>Shiiya</surname><given-names>T</given-names></name>
<name><surname>Nakazato</surname><given-names>M</given-names></name>
</person-group>. <article-title>Translational research of ghrelin</article-title>. <source>Ann N Y Acad Sci</source>. <year>2010</year>;<volume>1200</volume>:<fpage>120</fpage>-<lpage>127</lpage>.</citation>
</ref>
<ref id="bibr43-0148607111413770">
<label>43.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lee</surname><given-names>SH</given-names></name>
<name><surname>Kim</surname><given-names>YD</given-names></name>
<name><surname>Kong</surname><given-names>YH</given-names></name>
<etal/>
</person-group>. <article-title>The relevance of serum ghrelin concentration to severity of acute pancreatitis</article-title>. <source>Gut Liver</source>. <year>2010</year>;<volume>4</volume>:<fpage>234</fpage>-<lpage>210</lpage>.</citation>
</ref>
<ref id="bibr44-0148607111413770">
<label>44.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kadoglou</surname><given-names>NP</given-names></name>
<name><surname>Lampropoulos</surname><given-names>S</given-names></name>
<name><surname>Kapelouzou</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Serum levels of apelin and ghrelin in patients with acute coronary syndromes and established coronary artery disease—KOZANI STUDY</article-title>. <source>Transl Res</source>. <year>2010</year>;<volume>155</volume>:<fpage>238</fpage>-<lpage>246</lpage>.</citation>
</ref>
<ref id="bibr45-0148607111413770">
<label>45.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Koch</surname><given-names>A</given-names></name>
<name><surname>Sanson</surname><given-names>E</given-names></name>
<name><surname>Helm</surname><given-names>A</given-names></name>
<name><surname>Voigt</surname><given-names>S</given-names></name>
<name><surname>Trautwein</surname><given-names>C</given-names></name>
<name><surname>Tacke</surname><given-names>F</given-names></name>
</person-group>. <article-title>Regulation and prognostic relevance of serum ghrelin concentrations in critical illness and sepsis</article-title>. <source>Crit Care</source>. <year>2010</year>;<volume>14</volume>:<fpage>R94</fpage>-<lpage>R103</lpage>.</citation>
</ref>
<ref id="bibr46-0148607111413770">
<label>46.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Landzinski</surname><given-names>J</given-names></name>
<name><surname>Kiser</surname><given-names>TH</given-names></name>
<name><surname>Fish</surname><given-names>DN</given-names></name>
<name><surname>Wischmeyer</surname><given-names>PE</given-names></name>
<name><surname>MacLaren</surname><given-names>R</given-names></name>
</person-group>. <article-title>Gastric motility function in critically ill patients tolerant versus intolerant to gastric nutrition</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2008</year>;<volume>32</volume>:<fpage>45</fpage>-<lpage>50</lpage>.</citation>
</ref>
<ref id="bibr47-0148607111413770">
<label>47.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>MacLaren</surname><given-names>R</given-names></name>
<name><surname>Kiser</surname><given-names>TH</given-names></name>
<name><surname>Fish</surname><given-names>DN</given-names></name>
<name><surname>Wischmeyer</surname><given-names>PE</given-names></name>
</person-group>. <article-title>Erythromycin versus metoclopramide for facilitating gastric emptying and tolerance to intragastric nutrition</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2008</year>;<volume>32</volume>:<fpage>412</fpage>-<lpage>419</lpage>.</citation>
</ref>
<ref id="bibr48-0148607111413770">
<label>48.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Romero</surname><given-names>A</given-names></name>
<name><surname>Kirchner</surname><given-names>H</given-names></name>
<name><surname>Heppner</surname><given-names>K</given-names></name>
<name><surname>Pfluger</surname><given-names>PT</given-names></name>
<name><surname>Tschöp</surname><given-names>MH</given-names></name>
<name><surname>Nogueiras</surname><given-names>R</given-names></name>
</person-group>. <article-title>GOAT: the master switch for the ghrelin system?</article-title> <source>Eur J Endocrinol</source>. <year>2010</year>;<volume>163</volume>:<fpage>1</fpage>-<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr49-0148607111413770">
<label>49.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schmidt</surname><given-names>A</given-names></name>
<name><surname>Fabrizii</surname><given-names>V</given-names></name>
<name><surname>Maier</surname><given-names>C</given-names></name>
<etal/>
</person-group>. <article-title>Normal regulation of elevated plasma ghrelin concentrations in dialysis patients</article-title>. <source>Wien Klin Wochenschr</source>. <year>2004</year>;<volume>116</volume>:<fpage>235</fpage>-<lpage>239</lpage>.</citation>
</ref>
<ref id="bibr50-0148607111413770">
<label>50.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Goodyear</surname><given-names>SJ</given-names></name>
<name><surname>Mottershead</surname><given-names>M</given-names></name>
<name><surname>Sung</surname><given-names>EZ</given-names></name>
<etal/>
</person-group>. <article-title>Dysregulation of plasma ghrelin in alcoholic cirrhosis</article-title>. <source>Clin Endocrinol</source>. <year>2010</year>;<volume>73</volume>:<fpage>323</fpage>-<lpage>329</lpage>.</citation>
</ref>
<ref id="bibr51-0148607111413770">
<label>51.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>El-Shehaby</surname><given-names>AM</given-names></name>
<name><surname>Obaia</surname><given-names>EM</given-names></name>
<name><surname>Alwakil</surname><given-names>SS</given-names></name>
<name><surname>Hiekal</surname><given-names>AA</given-names></name>
</person-group>. <article-title>Total and acylated ghrelin in liver cirrhosis: correlation with clinical and nutritional status</article-title>. <source>Scand J Clin Lab Invest</source>. <year>2010</year>;<volume>70</volume>:<fpage>252</fpage>-<lpage>258</lpage>.</citation>
</ref>
<ref id="bibr52-0148607111413770">
<label>52.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tacke</surname><given-names>F</given-names></name>
<name><surname>Brabant</surname><given-names>G</given-names></name>
<name><surname>Kruck</surname><given-names>E</given-names></name>
<etal/>
</person-group>. <article-title>Ghrelin in chronic liver disease</article-title>. <source>J Hepatol</source>. <year>2003</year>;<volume>38</volume>:<fpage>447</fpage>-<lpage>454</lpage>.</citation>
</ref>
<ref id="bibr53-0148607111413770">
<label>53.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yalniz</surname><given-names>M</given-names></name>
<name><surname>Bahcecioglu</surname><given-names>IH</given-names></name>
<name><surname>Ataseven</surname><given-names>H</given-names></name>
<etal/>
</person-group>. <article-title>Serum adipokine and ghrelin levels in nonalcoholic steatohepatitis</article-title>. <source>Mediators Inflamm</source>. <year>2006</year>;<volume>2006</volume>:<fpage>78360</fpage>.</citation>
</ref>
<ref id="bibr54-0148607111413770">
<label>54.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cohen</surname><given-names>RI</given-names></name>
<name><surname>Tsang</surname><given-names>D</given-names></name>
<name><surname>Koenig</surname><given-names>S</given-names></name>
<name><surname>Wilson</surname><given-names>D</given-names></name>
<name><surname>McCloskey</surname><given-names>T</given-names></name>
<name><surname>Chandra</surname><given-names>S</given-names></name>
</person-group>. <article-title>Plasma ghrelin and leptin in adult cystic fibrosis patients</article-title>. <source>J Cyst Fibros</source>. <year>2008</year>;<volume>7</volume>:<fpage>298</fpage>-<lpage>402</lpage>.</citation>
</ref>
<ref id="bibr55-0148607111413770">
<label>55.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nematy</surname><given-names>M</given-names></name>
<name><surname>Brynes</surname><given-names>AE</given-names></name>
<name><surname>Hornick</surname><given-names>PI</given-names></name>
<etal/>
</person-group>. <article-title>Postprandial ghrelin suppression is exaggerated following major surgery: implications for nutritional recovery</article-title>. <source>Nutr Metab</source>. <year>2007</year>;<volume>4</volume>:<fpage>20</fpage>.</citation>
</ref>
<ref id="bibr56-0148607111413770">
<label>56.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nematy</surname><given-names>M</given-names></name>
<name><surname>O’Flynn</surname><given-names>JE</given-names></name>
<name><surname>Wandrag</surname><given-names>L</given-names></name>
<etal/>
</person-group>. <article-title>Changes in appetite related gut hormones in intensive care unit patients: a pilot cohort study</article-title>. <source>Crit Care</source>. <year>2006</year>;<volume>10</volume>:<fpage>R10</fpage>-<lpage>R19</lpage>.</citation>
</ref>
<ref id="bibr57-0148607111413770">
<label>57.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nguyen</surname><given-names>NQ</given-names></name>
<name><surname>Fraser</surname><given-names>RJ</given-names></name>
<name><surname>Bryant</surname><given-names>LK</given-names></name>
<name><surname>Chapman</surname><given-names>M</given-names></name>
<name><surname>Holloway</surname><given-names>RH</given-names></name>
</person-group>. <article-title>Diminished functional association between proximal and distal gastric motility in critically ill patients</article-title>. <source>Intensive Care Med</source>. <year>2008</year>;<volume>34</volume>:<fpage>1246</fpage>-<lpage>1255</lpage>.</citation>
</ref>
<ref id="bibr58-0148607111413770">
<label>58.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chen</surname><given-names>Z</given-names></name>
<name><surname>Wang</surname><given-names>S</given-names></name>
<name><surname>Yu</surname><given-names>B</given-names></name>
<name><surname>Li</surname><given-names>A</given-names></name>
</person-group>. <article-title>A comparison study between early enteral nutrition and parenteral nutrition in severe burn patients</article-title>. <source>Burns</source>. <year>2007</year>;<volume>33</volume>:<fpage>708</fpage>-<lpage>712</lpage>.</citation>
</ref>
<ref id="bibr59-0148607111413770">
<label>59.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McClave</surname><given-names>SA</given-names></name>
<name><surname>Snider</surname><given-names>HL</given-names></name>
</person-group>. <article-title>Clinical use of gastric residual volumes as a monitor for patients on enteral tube feeding</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2002</year>;<volume>26</volume>(<issue>suppl</issue>):<fpage>S43</fpage>-<lpage>S50</lpage>.</citation>
</ref>
<ref id="bibr60-0148607111413770">
<label>60.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Metheny</surname><given-names>NA</given-names></name>
</person-group>. <article-title>Preventing respiratory complications of tube feedings: evidence-based practice</article-title>. <source>Am J Crit Care</source>. <year>2006</year>;<volume>15</volume>:<fpage>360</fpage>-<lpage>369</lpage>.</citation>
</ref>
<ref id="bibr61-0148607111413770">
<label>61.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mallampalli</surname><given-names>A</given-names></name>
<name><surname>McClave</surname><given-names>SA</given-names></name>
<name><surname>Snider</surname><given-names>HL</given-names></name>
</person-group>. <article-title>Defining tolerance to enteral feeding in the intensive care unit</article-title>. <source>Clin Nutr</source>. <year>2000</year>;<volume>19</volume>:<fpage>213</fpage>-<lpage>215</lpage>.</citation>
</ref>
<ref id="bibr62-0148607111413770">
<label>62.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McClave</surname><given-names>SA</given-names></name>
<name><surname>Lukan</surname><given-names>JK</given-names></name>
<name><surname>Stefater</surname><given-names>JA</given-names></name>
<etal/>
</person-group>. <article-title>Poor validity of residual volumes as a marker for risk of aspiration in critically ill patients</article-title>. <source>Crit Care Med</source>. <year>2005</year>;<volume>33</volume>:<fpage>324</fpage>-<lpage>330</lpage>.</citation>
</ref>
<ref id="bibr63-0148607111413770">
<label>63.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Metheny</surname><given-names>NA</given-names></name>
<name><surname>Clouse</surname><given-names>RE</given-names></name>
<name><surname>Chang</surname><given-names>YH</given-names></name>
<name><surname>Stewart</surname><given-names>BJ</given-names></name>
<name><surname>Oliver</surname><given-names>DA</given-names></name>
<name><surname>Kollef</surname><given-names>MH</given-names></name>
</person-group>. <article-title>Tracheobronchial aspiration of gastric contents in critically ill tube-fed patients: frequency, outcomes, and risk factors</article-title>. <source>Crit Care Med</source>. <year>2006</year>;<volume>34</volume>:<fpage>1007</fpage>-<lpage>1015</lpage>.</citation>
</ref>
<ref id="bibr64-0148607111413770">
<label>64.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Montejo</surname><given-names>JC</given-names></name>
<name><surname>Minambres</surname><given-names>E</given-names></name>
<name><surname>Bordeje</surname><given-names>L</given-names></name>
<etal/>
</person-group>. <article-title>Gastric residual volume during enteral nutrition in ICU patients: the REGANE study</article-title>. <source>Intensive Care Med</source>. <year>2010</year>;<volume>36</volume>:<fpage>1386</fpage>-<lpage>1393</lpage>.</citation>
</ref>
<ref id="bibr65-0148607111413770">
<label>65.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Taylor</surname><given-names>SJ</given-names></name>
<name><surname>Fettes</surname><given-names>SB</given-names></name>
<name><surname>Jewkes</surname><given-names>C</given-names></name>
<name><surname>Nelson</surname><given-names>RJ</given-names></name>
</person-group>. <article-title>Prospective, randomized, controlled trial to determine the effect of early enhanced enteral nutrition on clinical outcome in mechanically ventilated patients suffering head injury</article-title>. <source>Crit Care Med</source>. <year>1999</year>;<volume>27</volume>:<fpage>2525</fpage>-<lpage>2531</lpage>.</citation>
</ref>
<ref id="bibr66-0148607111413770">
<label>66.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pinilla</surname><given-names>JC</given-names></name>
<name><surname>Samphire</surname><given-names>J</given-names></name>
<name><surname>Arnold</surname><given-names>C</given-names></name>
<name><surname>Liu</surname><given-names>L</given-names></name>
<name><surname>Thiessen</surname><given-names>B</given-names></name>
</person-group>. <article-title>Comparison of gastrointestinal tolerance to two enteral feeding protocols in critically ill patients: a prospective, randomized controlled trial</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2001</year>;<volume>25</volume>:<fpage>81</fpage>-<lpage>86</lpage>.</citation>
</ref>
<ref id="bibr67-0148607111413770">
<label>67.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Poulard</surname><given-names>F</given-names></name>
<name><surname>Dimet</surname><given-names>J</given-names></name>
<name><surname>Martin-Lefevre</surname><given-names>L</given-names></name>
<etal/>
</person-group>. <article-title>Impact of not measuring residual gastric volume in mechanically ventilated patients receiving early enteral feeding: a prospective before-after study</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2010</year>;<volume>34</volume>:<fpage>125</fpage>-<lpage>130</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>